Show simple item record

dc.contributor.authorAl-Nazal, Hanan A
dc.contributor.authorCooper, Emily
dc.contributor.authorHo, Mei Fong
dc.contributor.authorEskandari, Sharareh
dc.contributor.authorMajam, Victoria
dc.contributor.authorGiddam, Ashwini Kumar
dc.contributor.authorHussein, Waleed M
dc.contributor.authorIslam, Md Tanjir
dc.contributor.authorSkwarczynski, Mariusz
dc.contributor.authorToth, Istvan
dc.contributor.authorKumar, Sanjai
dc.contributor.authorZaid, Ali
dc.contributor.authorBatzloff, Michael
dc.contributor.authorStanisic, Danielle I
dc.contributor.authorGood, Michael F
dc.description.abstractBabesia spp. are tick-transmitted intra-erythrocytic protozoan parasites that infect humans and animals, causing a flu-like illness and hemolytic anemia. There is currently no human vaccine available. People most at risk of severe disease are the elderly, immunosuppressed, and asplenic individuals. B. microti and B. divergens are the predominant species affecting humans. Here, we present a whole-parasite Babesia vaccine. To establish proof-of-principle, we employed chemically attenuated B. microti parasitized red blood cells from infected mice. To aid clinical translation, we produced liposomes containing killed parasite material. Vaccination significantly reduces peak parasitemia following challenge. B cells and anti-parasite antibodies do not significantly contribute to vaccine efficacy. Protection is abrogated by the removal of CD4+ T cells or macrophages prior to challenge. Importantly, splenectomized mice are protected by vaccination. To further facilitate translation, we prepared a culture-based liposomal vaccine and demonstrate that this performs as a universal vaccine inducing immunity against different human Babesia species.
dc.publisherElsevier BV
dc.relation.ispartofjournalCell Host & Microbe
dc.subject.fieldofresearchMedical microbiology
dc.subject.keywordsB. divergens
dc.subject.keywordsB. microti
dc.subject.keywordsT cells
dc.subject.keywordsheterologous protection
dc.titlePre-clinical evaluation of a whole-parasite vaccine to control human babesiosis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationAl-Nazal, HA; Cooper, E; Ho, MF; Eskandari, S; Majam, V; Giddam, AK; Hussein, WM; Islam, MT; Skwarczynski, M; Toth, I; Kumar, S; Zaid, A; Batzloff, M; Stanisic, DI; Good, MF, Pre-clinical evaluation of a whole-parasite vaccine to control human babesiosis, Cell Host & Microbe, 2021
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.hasfulltextNo Full Text
gro.griffith.authorGood, Michael F.
gro.griffith.authorStanisic, Danielle
gro.griffith.authorEskandari, Sherry
gro.griffith.authorAl-Nazal, Hanan A.
gro.griffith.authorCooper, Emily K.
gro.griffith.authorHo, Mei Fong
gro.griffith.authorGiddam, Ashwin Kumar K.
gro.griffith.authorZaid, Ali
gro.griffith.authorBatzloff, Michael R.

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record